Jade Biosciences, Inc. - 8-K Filing
On June 25, 2026, Jade Biosciences appointed Mark Eisner, M.D., M.P.H. as a Class I director to serve until the 2028 annual meeting or earlier resignation/removal. Dr. Eisner received a stock option for 47,675 shares vesting over three years and will receive an annual cash retainer under the company's non-employee director compensation program. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure On June 26, 2026, the Company issued a press release announcing Dr, 9.01 Financial Statements and Exhibits)
Tickers: $AVTE